How Cynata Therapeutics is unlocking the power of iPSCs to transform regenerative medicine

/in ,

How Cynata Therapeutics is unlocking the power of iPSCs to transform regenerative medicine Cynata Therapeutics, a Melbourne, Australia-based regenerative medicine company, is pioneering a new era in cell therapy with its Cymerus platform. Built on the foundation of induced pluripotent stem cell (iPSC) technology, Cynata’s approach offers a transformative alternative to traditional mesenchymal stem cell […]

Read more

Four in five Aussie asthma sufferers to breathe easier under new technology

/in , ,

Four in five Aussie asthma sufferers to breathe easier under new technology Tuesday, 29 April 2025 More than 2.2 million Australian people with asthma could benefit from life-changing digital inhaler technology which has the potential to save lives and ease the burden on Australia’s strained healthcare system.   Approximately 2.8 million Australians have a diagnosis […]

Read more

Promising efficacy data in preclinical studies of Cymerus MSCs in heart disease

/in ,

Promising efficacy data in preclinical studies of Cymerus MSCs in heart disease Melbourne, Australia; 7 April 2025 Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”,or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, today announced positive efficacy data observed in preclinical studies conducted with Cynata’s Cymerus™ iPSC[1]-derived MSCs[2] in models of ischaemic heart disease. MSCs […]

Read more